Ligand Activation of ERRα by Cholesterol Mediates Statin and Bisphosphonate Effects

•The ERRα-LBD selectively enriches cholesterol from the lipidome•ERRα transcriptional activity is enhanced by cholesterol and suppressed by statins•ERRα confers cholesterol regulation in osteoclasts, macrophages, and myocytes•ERRα mediates statin- and bisphosphonate-induced pharmacological effects

SummaryNuclear receptors (NRs) are key regulators of gene expression and physiology. Nearly half of all human NRs lack endogenous ligands including estrogen-related receptor α (ERRα). ERRα has important roles in cancer, metabolism, and skeletal homeostasis. Affinity chromatography of tissue lipidomes with the ERRα ligand-binding domain (LBD) and subsequent transcriptional assays identified cholesterol as an endogenous ERRα agonist. Perturbation of cholesterol biosynthesis or inhibition of ERRα revealed the interdependence of cholesterol and ERRα. In bone, the effects of cholesterol, statin, and bisphosphonate on osteoclastogenesis require ERRα; and consequently, cholesterol-induced bone loss or bisphosphonate osteoprotection is lost in ERRα knockout mice. Furthermore, statin induction of muscle toxicity and cholesterol suppression of macrophage cytokine secretion are impaired by loss or inhibition of ERRα. These findings reveal a key step in ERRα regulation and explain the actions of two highly prescribed drugs, statins and bisphosphonates.

Graphical AbstractFigure optionsDownload full-size imageDownload high-quality image (179 K)Download as PowerPoint slide